What they're not telling you: # Trump Says He's Not Replacing FDA Chief Makary President Trump publicly denied plans to remove FDA Commissioner Marty Makary on May 8, directly contradicting multiple media reports claiming the administration intended to oust him over his handling of the abortion drug mifepristone. The denial came as Trump fielded reporter questions outside the White House. When asked about Makary's future, Trump offered minimal commentary: "Nothing much, he's doing fine," and stated he knew "nothing about it" regarding reports of a planned removal.
# THE TAKE: Trump's FDA Loyalty Theater Doesn't Pass the Sniff Test Trump claims Makary stays. Fine. But let's document what actually happened: Makary spent months publicly undermining RFK Jr.'s bird flu narrative while Trump championed it. They're ideological opponents on raw milk, gain-of-function research, and vaccine theology. This statement conveniently drops *after* Makary testified to Congress in April—buying Trump political cover without committing to anything. Classic misdirection. The real tell? Trump hasn't publicly defended Makary's actual policies. He's defending the *optics* of stability. Makary keeps his job only so long as he doesn't publicly contradict MAGA orthodoxy. The moment he does, Trump will cite this exact "no plans to replace" quote while doing exactly that. Welcome to loyalty theater: the commitment that disappears on impact.
What the Documents Show
The president's refusal to elaborate, combined with his explicit rejection of hiring a replacement, suggests either genuine confidence in Makary's leadership or a calculated decision to publicly distance the administration from personnel turbulence. White House spokesman Kush Desai amplified the message, asserting that Trump "has assembled the most experienced and talented administration in history." Yet the timing of Trump's statement matters. Multiple news outlets had cited unnamed sources on May 8—the same day as Trump's denial—claiming the administration intended to remove Makary following a Fifth Circuit Court of Appeals ruling that blocked mailed distribution of mifepristone. That May 1 decision stated the FDA "conceded it had failed to adequately study whether remotely prescribing mifepristone is safe." The Supreme Court later placed the appeals court ruling on hold after Danco Laboratories, the pill's manufacturer, requested an emergency stay. Notably, mifepristone had been available via mail and pharmacies since 2023 after federal authorities expanded access.
Follow the Money
The pressure on Makary came explicitly from pro-life advocacy groups. Anthony (SBA) Pro-Life America called for his immediate termination, accusing him of indifference toward stricter abortion drug regulations. "FDA Commissioner Makary should be fired immediately," SBA Pro-Life America President Marjorie Dannenfel stated. "Indifference is completely unacceptable to millions of pro-life voters expecting the administration to act to save lives." This public demand from a constituency Trump depends on creates a tension that Trump's denial may be designed to defuse—by appearing to retain Makary while potentially shifting FDA policy through other channels. The episode exposes a gap between behind-the-scenes pressure and public messaging. Mainstream outlets reported the removal plans based on anonymous sources, yet Trump's public stance emphasizes stability and confidence in Makary's competence.
What Else We Know
What remains unclear is whether the administration plans to modify mifepristone policy through regulatory action independent of commissioner changes, or whether pro-life groups' demands will intensify if policy shifts don't materialize. For ordinary Americans, this dynamic matters directly: the mifepristone controversy centers on medication access and FDA approval standards. Whether Makary remains in place or not, the Fifth Circuit's safety concerns and ongoing Supreme Court proceedings will determine whether women can continue accessing the drug remotely. Trump's public support for Makary may indicate that personnel stability, rather than immediate policy reversals, is the administration's current strategy—but the underlying regulatory battles continue regardless of who leads the FDA.
Primary Sources
- Source: ZeroHedge
- Category: Government Secrets
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.